Early aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report.

Hdl Handle:
http://hdl.handle.net/10147/127651
Title:
Early aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report.
Authors:
Peshin, R; O'Neill, L; Browne, P; O'Connell, P; Kearns, G
Affiliation:
Department of Rheumatology, Beaumont Hospital, Dublin, Republic of Ireland. rohit_peshin@yahoo.com
Citation:
Early aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report. 2009, 28 Suppl 1:S31-4 Clin. Rheumatol.
Journal:
Clinical rheumatology
Issue Date:
Jun-2009
URI:
http://hdl.handle.net/10147/127651
DOI:
10.1007/s10067-009-1098-y
PubMed ID:
19194736
Abstract:
Interstitial lung disease is an important cause of mortality and morbidity in patients with systemic sclerosis (SSc). There are currently no recommended guidelines for management of these patients. This is probably due to the rarity of this condition, as well as clinical trials with only a small number of cases. There are published case report and case series along with the two main trials, viz. Scleroderma Lung Study and the Fibrosing Alveolitis Study, but again, there is no consensus on treatment protocols. In this report, we present a case of aggressive interstitial lung disease in a patient with SSc, which improved dramatically on treatment with intra-venous cyclophosphamide and high dose prednisolone therapy.
Item Type:
Article
Language:
en
MeSH:
Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Male; Middle Aged; Prednisolone; Scleroderma, Systemic
ISSN:
1434-9949

Full metadata record

DC FieldValue Language
dc.contributor.authorPeshin, Ren
dc.contributor.authorO'Neill, Len
dc.contributor.authorBrowne, Pen
dc.contributor.authorO'Connell, Pen
dc.contributor.authorKearns, Gen
dc.date.accessioned2011-04-07T09:10:55Z-
dc.date.available2011-04-07T09:10:55Z-
dc.date.issued2009-06-
dc.identifier.citationEarly aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report. 2009, 28 Suppl 1:S31-4 Clin. Rheumatol.en
dc.identifier.issn1434-9949-
dc.identifier.pmid19194736-
dc.identifier.doi10.1007/s10067-009-1098-y-
dc.identifier.urihttp://hdl.handle.net/10147/127651-
dc.description.abstractInterstitial lung disease is an important cause of mortality and morbidity in patients with systemic sclerosis (SSc). There are currently no recommended guidelines for management of these patients. This is probably due to the rarity of this condition, as well as clinical trials with only a small number of cases. There are published case report and case series along with the two main trials, viz. Scleroderma Lung Study and the Fibrosing Alveolitis Study, but again, there is no consensus on treatment protocols. In this report, we present a case of aggressive interstitial lung disease in a patient with SSc, which improved dramatically on treatment with intra-venous cyclophosphamide and high dose prednisolone therapy.-
dc.language.isoenen
dc.subject.meshAnti-Inflammatory Agents-
dc.subject.meshAntineoplastic Agents, Alkylating-
dc.subject.meshCyclophosphamide-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshLung Diseases, Interstitial-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPrednisolone-
dc.subject.meshScleroderma, Systemic-
dc.titleEarly aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report.en
dc.typeArticleen
dc.contributor.departmentDepartment of Rheumatology, Beaumont Hospital, Dublin, Republic of Ireland. rohit_peshin@yahoo.comen
dc.identifier.journalClinical rheumatologyen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.